- 期刊
- OpenAccess
Type 1 Diabetes Mellitus Associated with Pegylated Interferon-a Plus Ribavirin Treatment for Chronic Hepatitis C: Case Report and Literature Review
並列摘要
Combined pegylated interferon (PEG-IFN)+ribavirin (RBV) therapy has been used as a primary treatment for chronic hepatitis C. However, IFN-induced autoimmune disease, including type 1 diabetes mellitus, has been highlighted as one of the problems with this therapy. Here we report the case of a patient who developed type 1 diabetes mellitus during combined PEG-IFN+RBV therapy for hepatitis C but who showed no exacerbation of diabetes despite continued use of IFN. A 63-year-old man with chronic hepatitis C and a nonresponder to previous IFNα treatments, was admitted to our hospital because of excessive thirst, polydipsia, and polyuria 24 weeks after the start of PEG-IFNα+RBV therapy. High levels of blood glucose and glycosylated hemoglobin and low levels of C-peptide and immunoreactive insulin were observed. The serum antiglutamic acid decarboxylase antibody titer was 27,700 U/mL. We diagnosed IFN-induced type 1 diabetes mellitus; however PEG-IFNα+RBV therapy was continued for 48 weeks. Serum HCV remains negative five years after this treatment. Intensive insulin therapy was started immediately after the diagnosis of type 1 diabetes. Although the patient initially required 22 U/day of insulin, the dosage could be gradually reduced after completion of PEG-IFNα+RBV therapy and blood glucose remained well controlled. Prediction of onset of type 1 diabetes mellitus on the basis of baseline measurement of pancreas- associated autoantibodies is difficult. Therefore, it would be advisable to consider the possibility of onset of type 1 diabetes mellitus in all patients receiving IFN+RBV therapy.
延伸閱讀
- 梁程超（2009）。The Number and Function of Dendritic Cells in Patients with Hepatitis C Virus Genotype 1 Infection Treated with Pegylated Interferon plus Ribavirin〔碩士論文，國立臺灣大學〕。華藝線上圖書館。https://doi.org/10.6342/NTU.2009.01370
- Huri, H. Z., Selamat, N., & Vethakkan, S. R. (2014). Factors Associated with Utilization of Dipeptidyl-4 Inhibitors in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Retrospective Study. International Journal of Endocrinology, 2014(), 657-663-070. https://doi.org/10.1155/2014/367564
- 吳俊男（2012）。The Influenced factors of the Efficacy and Anemia Adverse Effects Induced by Pegylated Interferon Alpha plus Ribavirin in Chronic Hepatitis C〔碩士論文，中山醫學大學〕。華藝線上圖書館。https://doi.org/10.6834/CSMU.2012.00119
- Wen, S. C., Cheng, L. C., Hsu, J. H., Shih, P. C., Tsai, C. C., & Kuo, W. H. (2016). Assessment of Factors Correlated with Ribavirin Dose Reduction Due to Hemolytic Anemia during Treatment in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin Combination Therapy. 寶建醫護與管理雜誌, 13(1&2), 1-8. https://www.airitilibrary.com/Article/Detail?DocID=16830806-201606-201701130020-201701130020-1-8
- Lin, Y. H., Lin, J. L., Wang, C. H., & Chien, M. N. (2013). Non-Islet Cell Tumor-Induced Hypoglycemia in Type 2 Diabetes Mellitus - A Case Report and the Literature Review. Formosan Journal of Endocrinology and Metabolism, 4(1), 13-17. https://doi.org/10.6856/FJEM.201306_4(1).0004